EvoDenovo - Crunchbase Company Profile & Funding

Overview

EvoDenovo

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About EvoDenovo

CB Rank

586144

EvoDenovo is a drug development company designing medicines to limit opioid dependence while improving analgesia.

Founded

obfuscation

Private

Woburn, Massachusetts, United States

1-10

www.evodenovo.us/

Pharmaceutical

Key People

sid ahmed labed: CEO

Details

Legal Name

EvoDenovo, Inc.

Also Known As

EvoD

Operating Status

Active

Company Type

For Profit

Founders

Fred Ausubel, Kirill Martemyanov, sid ahmed labed

About the Company

EvoDenovo is a drug development company designing medicines to limit opioid dependence while improving pain relief. Through our technology, withdrawal symptoms from opioids are drastically reduced while beneficial analgesic effects are enhanced.

Contact Email

sid@evodenovo.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Anti-Opioid System

A system designed to counteract opioid signaling by interacting with the mu-opioid receptor, aiming to reduce opioid side effects while enhancing analgesic effects.

Biologic Therapeutics for Depression

Proprietary nanobody technology developed to provide rapid, targeted, and long-lasting relief from depression, addressing limitations of traditional antidepressants.